Stock listing
NASDAQ:PCVX Vaxcyte, Inc. Stock
Home listing (NASDAQ) of Vaxcyte, Inc.
Follow Vaxcyte, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:PCVX
$60.43 USD -2.42 (-3.9%)
Close on Oct 23, 2026
- Day range
- $60.27 – $62.77 USDOct 23, 2026
- Volume
- 2.06M sharesOct 23, 2026
- Market cap
- $9.51B USDAt the close on Oct 23, 2026 · price × 157.4M shares outstanding
- 52-week range
- $39.87 – $90.75 USDLowest and highest trades, Oct 24, 2025 – Oct 23, 2026
Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:PCVX · Home | $60.43 USD | -2.42 (-3.9%) | 2,062,400 | $62.35 | $62.77 | $60.27 | $62.85 | Close on Oct 23, 2026 |
| Frankfurt:5VA | €53.00 EUR | +0.50 (+1.0%) | — | €53.00 | €53.00 | €53.00 | €52.50 | Close on Oct 23, 2026 |
Daily closes
Last 3 months, Jul 23, 2026 – Oct 23, 2026 · NASDAQ:PCVX · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $60.43 | -2.42 | -3.9% | $62.35 | $62.77 | $60.27 | 2,062,400 | |
| $62.85 | -0.38 | -0.6% | $62.96 | $64.58 | $61.56 | 2,771,300 | |
| $63.23 | -3.00 | -4.5% | $66.02 | $67.47 | $63.09 | 3,272,200 | |
| $66.23 | +2.55 | +4.0% | $63.80 | $67.01 | $63.68 | 1,956,700 | |
| $63.68 | +0.06 | +0.1% | $64.14 | $66.02 | $63.38 | 2,549,200 | |
| $63.62 | -1.65 | -2.5% | $65.13 | $65.34 | $62.54 | 3,249,900 | |
| $65.27 | -2.28 | -3.4% | $67.72 | $68.33 | $65.00 | 2,448,500 | |
| $67.55 | +0.75 | +1.1% | $67.07 | $69.21 | $66.00 | 1,525,200 | |
| $66.80 | -3.85 | -5.4% | $70.58 | $71.09 | $66.63 | 2,644,900 | |
| $70.65 | -0.73 | -1.0% | $71.08 | $72.89 | $68.97 | 2,427,600 | |
| $71.38 | +6.365 | +9.8% | $64.78 | $72.44 | $64.78 | 4,381,400 | |
| $65.02 | -1.945 | -2.9% | $67.14 | $67.97 | $63.79 | 3,848,100 | |
| $66.96 | +0.26 | +0.4% | $65.86 | $67.15 | $64.27 | 11,561,100 | |
| $66.70 | -7.12 | -9.6% | $73.35 | $73.40 | $63.90 | 10,156,100 | |
| $73.82 | +17.34 | +30.7% | $87.21 | $90.75 | $71.60 | 14,924,000 | |
| $56.48 | +0.43 | +0.8% | $56.76 | $57.00 | $55.84 | 2,399,600 | |
| $56.05 | -0.85 | -1.5% | $56.73 | $57.17 | $56.00 | 1,166,200 | |
| $56.90 | +0.21 | +0.4% | $56.69 | $57.51 | $56.13 | 1,508,700 | |
| $56.69 | -1.58 | -2.7% | $57.96 | $58.98 | $55.91 | 1,493,500 | |
| $58.27 | +2.06 | +3.7% | $56.50 | $58.82 | $55.75 | 1,849,000 | |
| $56.21 | -0.69 | -1.2% | $57.22 | $57.50 | $55.92 | 947,300 | |
| $56.90 | +0.405 | +0.7% | $55.86 | $57.59 | $55.09 | 1,852,000 | |
| $56.50 | -2.525 | -4.3% | $59.02 | $59.10 | $55.09 | 1,650,400 | |
| $59.02 | +0.10 | +0.2% | $59.45 | $59.96 | $58.78 | 1,282,700 | |
| $58.92 | +0.79 | +1.4% | $59.00 | $60.54 | $57.62 | 1,124,400 | |
| $58.13 | -2.24 | -3.7% | $60.37 | $60.37 | $57.01 | 2,717,400 | |
| $60.37 | +1.60 | +2.7% | $60.22 | $61.50 | $59.31 | 1,309,200 | |
| $58.77 | -0.44 | -0.7% | $59.25 | $60.13 | $58.40 | 1,249,200 | |
| $59.21 | -0.33 | -0.6% | $59.70 | $59.75 | $58.19 | 1,887,900 | |
| $59.54 | +0.07 | +0.1% | $60.04 | $60.86 | $59.09 | 1,428,400 | |
| $59.47 | +0.57 | +1.0% | $60.07 | $60.20 | $58.21 | 1,683,400 | |
| $58.90 | -0.61 | -1.0% | $59.19 | $60.13 | $58.56 | 1,160,700 | |
| $59.51 | -0.85 | -1.4% | $59.99 | $60.33 | $59.05 | 1,195,200 | |
| $60.36 | -0.80 | -1.3% | $60.25 | $61.03 | $59.22 | 1,024,400 | |
| $61.16 | -0.01 | 0.0% | $59.73 | $61.78 | $59.65 | 986,700 | |
| $61.17 | -0.41 | -0.7% | $61.73 | $62.14 | $59.85 | 736,500 | |
| $61.58 | +0.77 | +1.3% | $61.63 | $62.90 | $60.82 | 1,021,300 | |
| $60.81 | +0.07 | +0.1% | $60.29 | $62.14 | $60.06 | 1,441,100 | |
| $60.74 | +0.905 | +1.5% | $59.10 | $61.61 | $58.51 | 1,749,000 | |
| $59.84 | -1.32 | -2.2% | $61.06 | $62.38 | $59.49 | 759,700 | |
| $61.16 | +0.065 | +0.1% | $60.51 | $61.60 | $59.93 | 611,600 | |
| $61.09 | 0.00 | 0.0% | $61.04 | $61.65 | $60.32 | 891,600 | |
| $61.09 | -0.78 | -1.3% | $62.22 | $63.92 | $60.96 | 1,217,884 | |
| $61.87 | -0.75 | -1.2% | $62.30 | $63.05 | $61.23 | 662,140 | |
| $62.62 | +1.28 | +2.1% | $61.60 | $63.98 | $61.60 | 1,141,500 | |
| $61.34 | -1.96 | -3.1% | $62.23 | $62.91 | $60.80 | 726,100 | |
| $63.30 | +3.51 | +5.9% | $61.56 | $63.83 | $60.95 | 1,444,900 | |
| $59.79 | -0.43 | -0.7% | $59.97 | $60.86 | $59.50 | 705,900 | |
| $60.22 | +2.15 | +3.7% | $58.03 | $60.29 | $57.34 | 712,900 | |
| $58.07 | -0.79 | -1.3% | $58.11 | $58.75 | $57.30 | 656,600 | |
| $58.86 | -0.79 | -1.3% | $60.00 | $60.45 | $58.72 | 839,100 | |
| $59.65 | +0.43 | +0.7% | $58.92 | $60.41 | $58.74 | 1,220,600 | |
| $59.22 | +0.93 | +1.6% | $58.72 | $59.65 | $57.83 | 796,800 | |
| $58.29 | +0.22 | +0.4% | $57.98 | $59.28 | $57.69 | 902,100 | |
| $58.07 | -0.82 | -1.4% | $59.91 | $60.08 | $56.74 | 1,296,300 | |
| $58.89 | +2.97 | +5.3% | $55.17 | $59.00 | $54.71 | 1,284,500 | |
| $55.92 | +1.23 | +2.2% | $55.00 | $56.75 | $54.94 | 886,300 | |
| $54.69 | +1.16 | +2.2% | $54.46 | $55.09 | $53.61 | 868,100 | |
| $53.53 | -0.55 | -1.0% | $53.99 | $54.49 | $52.77 | 774,800 | |
| $54.08 | -1.88 | -3.4% | $56.10 | $56.39 | $53.53 | 793,200 | |
| $55.96 | +2.98 | +5.6% | $52.95 | $56.21 | $52.50 | 817,900 | |
| $52.98 | -1.62 | -3.0% | $54.45 | $55.16 | $52.47 | 1,142,200 | |
| $54.60 | -0.90 | -1.6% | $55.93 | $57.03 | $54.04 | 1,301,600 | |
| $55.50 | +0.84 | +1.5% | $54.77 | $56.36 | $54.12 | 1,009,800 | |
| $54.66 | -0.98 | -1.8% | $55.81 | $55.81 | $54.28 | 1,120,700 | |
| $55.64 | -0.36 | -0.6% | $55.17 | $56.61 | $54.98 | 750,400 |
- Ticker
- NASDAQ:PCVX
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Oct 9, 2026
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
Latest earnings call · Feb 24, 2026
Vaxcyte (NASDAQ:PCVX) Q4 2025 Earnings Call
Replay and transcript
Latest deck · Oct 5, 2026
Technical Presentation (October 2026)
Technical · 34 slides
Calls
Replays
Vaxcyte (NASDAQ:PCVX) Q4 2025 Earnings Call
Tue, Feb 24, 2026 · 4:30 PM ET
Watch TranscriptVaxcyte (NASDAQ:PCVX) Q4 2024 Earnings Call
Tue, Feb 25, 2025 · 1:30 PM ET
Watch TranscriptVaxcyte (NASDAQ:PCVX) Q4 2023 Earnings Call
Tue, Feb 27, 2024 · 4:30 PM ET
Watch Transcript
Latest news
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
Oct 9, 2026
Closed $70.65 (-1.0%) on Oct 12, 2026
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
Oct 6, 2026
Closed $66.96 (+0.4%) on Oct 7, 2026
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
Oct 5, 2026
Closed $73.82 (+30.7%) on Oct 5, 2026
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
Sep 3, 2026
Closed $61.16 (0.0%) on Sep 4, 2026
Vaxcyte Reports Second Quarter 2026 Financial Results and Provides Business Update
Aug 5, 2026
Closed $58.89 (+5.3%) on Aug 6, 2026
Vaxcyte to Participate in Upcoming Investor Conferences
Jul 8, 2026
Closed $59.83 (+1.9%) on Jul 9, 2026
Vaxcyte Doses First Participant in Phase 1 Study Evaluating VAX-A1 for the Prevention of Disease Caused by Group A Streptococcus in Healthy Adults
Jun 2, 2026
Closed $46.93 (-1.0%) on Jun 3, 2026
Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business Update
May 6, 2026
Closed $51.48 (-9.8%) on May 7, 2026
Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare Conference
Apr 7, 2026
Closed $60.69 (+1.5%) on Apr 7, 2026
Financings
Public offering of common stock and pre-funded warrants
Oct 9, 2026
Closed: US$500M raised · US$64 a share · Jefferies +7
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), BofA Securities (co-lead), Evercore ISI (co-lead), Goldman Sachs & Co. LLC (co-lead), Guggenheim Securities (co-lead), Mizuho, BTIG
Use of proceeds: VAX-31 adult and pediatric clinical development, manufacturing scale-up, US launch preparation, early pipeline R&D and general corporate purposes
Announced Oct 5, 2026 · Update Oct 7, 2026 · Closed Oct 9, 2026
1.50% convertible senior notes due 2032
Oct 9, 2026
Closed: US$575M raised · Jefferies +8
Dealers: Jefferies (co-lead), Leerink Partners (co-lead), BofA Securities (co-lead), Goldman Sachs & Co. LLC (co-lead), Evercore ISI (co-lead), Guggenheim Securities, Mizuho, Needham & Company, J. Wood Capital Advisors
Use of proceeds: VAX-31 adult and pediatric clinical development, manufacturing scale-up, US launch preparation, early pipeline R&D and general corporate purposes
Announced Oct 5, 2026 · Update Oct 7, 2026 · Closed Oct 9, 2026
Decks
Technical Presentation (October 2026)
Technical · 34 slides · Oct 5, 2026
Technical Presentation (October 2026)
Technical · 35 slides · Oct 5, 2026
Investor Presentation (September 2026)
Investor deck · 80 slides · Sep 3, 2026
Q4 2025 Earnings Presentation
Earnings · 68 slides · Feb 24, 2026
Vaxcyte, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 25 in the last 12 months · 127 in all · newest Oct 9, 2026 · oldest 2020
- Calls
- 5 calls with a replay · 5 with a transcript · latest Feb 24, 2026
- Decks
- 9 decks · latest Oct 5, 2026
Where Vaxcyte, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:PCVX · Home listing · This page | NASDAQ | United States | USD |
| gettex:5VA | gettex | Germany | EUR |
| LS Exchange:A2P6R6 | LS Exchange | Germany | EUR |
| Lang & Schwarz:A2P6R6 | Lang & Schwarz | Germany | EUR |
| Milan:1PCVX | Milan | Italy | EUR |
| BOATS:PCVX | BOATS | United States | USD |
| Frankfurt:5VA | Frankfurt | Germany | EUR |
| BX Swiss:PCVX | BX Swiss | Switzerland | CHF |
| Dusseldorf:5VA | Dusseldorf | Germany | EUR |
| Hamburg:5VA | Hamburg | Germany | EUR |
| Munich:5VA | Munich | Germany | EUR |
| Stuttgart:5VA | Stuttgart | Germany | EUR |
| Tradegate:5VA | Tradegate | Germany | EUR |
| Hanover:5VA | Hanover | Germany | EUR |
| Xetra:5VA | Xetra | Germany | EUR |
Log in to ask 6ix AI your own questions about Vaxcyte, Inc.